- Home
- SPKL vs ETON Comparison
SPKL vs ETON Comparison
Compare SPKL & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- ETON
- Stock Information
- Founded
- SPKL 2021
- ETON 2017
- Country
- SPKL United States
- ETON United States
- Employees
- SPKL N/A
- ETON N/A
- Industry
- SPKL
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- SPKL
- ETON Health Care
- Exchange
- SPKL Nasdaq
- ETON Nasdaq
- Market Cap
- SPKL 170.5M
- ETON 199.5M
- IPO Year
- SPKL 2023
- ETON 2018
- Fundamental
- Price
- SPKL $10.56
- ETON $8.38
- Analyst Decision
- SPKL
- ETON Strong Buy
- Analyst Count
- SPKL 0
- ETON 3
- Target Price
- SPKL N/A
- ETON $10.33
- AVG Volume (30 Days)
- SPKL 14.8K
- ETON 198.4K
- Earning Date
- SPKL 01-01-0001
- ETON 11-07-2024
- Dividend Yield
- SPKL N/A
- ETON N/A
- EPS Growth
- SPKL N/A
- ETON N/A
- EPS
- SPKL 0.12
- ETON N/A
- Revenue
- SPKL N/A
- ETON $31,381,000.00
- Revenue This Year
- SPKL N/A
- ETON $19.61
- Revenue Next Year
- SPKL N/A
- ETON $35.39
- P/E Ratio
- SPKL $86.48
- ETON N/A
- Revenue Growth
- SPKL N/A
- ETON 8.14
- 52 Week Low
- SPKL $10.07
- ETON $3.03
- 52 Week High
- SPKL $11.57
- ETON $8.64
- Technical
- Relative Strength Index (RSI)
- SPKL 67.33
- ETON 81.47
- Support Level
- SPKL $10.45
- ETON $8.05
- Resistance Level
- SPKL $11.57
- ETON $8.64
- Average True Range (ATR)
- SPKL 0.12
- ETON 0.50
- MACD
- SPKL 0.01
- ETON 0.03
- Stochastic Oscillator
- SPKL 9.01
- ETON 90.15
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.